Gog 3057 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Gonzalez martinAmgen europeSeagen incBristol myers squibbMillenium pharmaceuticalsDeciphera pharmaceuticalsCarrick therapeuticsClovis oncologyElevar therapeuticsMolecular partnersVerastem oncologyTisotumab vedotinPatients with recurrent or metastatic cervical cancerNnovatv 301 trialEngot cx12 trialGog 3057 trial